Cytotoxicity of WT1-reactive T cells against Wilms tumor: An implication for antigen-specific adoptive immunotherapy

Introduction: T cells that recognize WT1 peptides have been shown to efficiently eliminate WT1-expressing tumor cells. This study was designed investigate the feasibility of isolating WT1-reactive from peripheral blood mononuclear (PBMCs) healthy donors and patients with Wilms tumor, assess cytotoxicity mediated by these against (WiTu cells). Methods: were enriched isolated stimulating PBMCs a peptide pool interferon-γ capture-based immunomagnetic separation (IMS). Using lactate dehydrogenase release assay, in vitro standard chemotherapy evaluated on WiTu Results: Higher proportions compared those HDs. produced > 50% specific lysis when co-cultured WT1+ at highest effector-to-target (E:T) ratio this (i.e., 5:1), <23% WT1- same ratio. showed anti-tumoral activity dose-dependent manner significantly greater than non-WT1-reactive fraction The lower E:T ratios 2:1 5:1. Conclusion: can be effectively tumor. Ex vivo generated might considered an adoptive immunotherapeutic option for tumors.